Potentially neuroprotective and therapeutic properties of nitrous oxide and xenon.
Despite the beneficial effects of prototypical glutamatergic receptor antagonists in animal models, the pharmacological attempts by the use of such agents have met with very limited clinical success because these compounds produce adverse side effects and possess an intrinsic neurotoxicity at neuroprotective and therapeutic concentrations. Interestingly, nitrous oxide and xenon, which are anesthetic gases with a remarkably safe clinical profile, have been shown to be effective inhibitors of the NMDA receptor. We briefly review accumulating evidence that nitrous oxide and xenon at subanesthetic concentrations may have potentially neuroprotective and therapeutic properties, with a particular focus on their beneficial effects on ischemia-induced neuronal death and amphetamine-induced sensitization. Nitrous oxide at 75-vol% and xenon up to 70-vol% reduce ischemia-induced neuronal death induced by occlusion of the middle cerebral artery in rodents, and decrease NMDA-induced Ca2+ influx in neuronal cell cultures, a critical event involved in excitotoxicity. Nitrous oxide at 75-vol% and xenon at 50-vol% further reduced amphetamine-induced locomotor sensitization in rodents. However, at a higher concentration of 75-vol%, xenon shows potentially neurotoxic properties and adverse side effects. Because both agents are rapidly eliminated from the body, it is plausible that their administration at appropriate subanesthetic neuroprotective and therapeutic concentrations may not be associated, in contrast with prototypical NMDA receptor antagonists, with adverse side effects and potentially neurotoxicity. Finally, the possible therapeutic implications in humans are discussed.
Abraini
Jacques H
JH
Centre CYCERON, UMR 6185, Université de Caen--CNRS, Boulevard Henri Becquerel, B. P. 5229, 14074 Caen cedex, France. abraini@cyceron.fr
David
Hélène N
HN
Lemaire
Marc
M
D018685:Anesthetics, Inhalation / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy / Q000473:pathology; D002315:Cardiopulmonary Bypass / Q000009:adverse effects; D016923:Cell Death / Q000187:drug effects; D000697:Central Nervous System Stimulants / Q000037:antagonists & inhibitors / Q000633:toxicity; D006801:Humans; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy / Q000473:pathology; D008694:Methamphetamine / Q000037:antagonists & inhibitors / Q000633:toxicity; D018696:Neuroprotective Agents; D009498:Neurotoxins / Q000037:antagonists & inhibitors / Q000633:toxicity; D009609:Nitrous Oxide / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D011183:Postoperative Complications / Q000517:prevention & control; D051381:Rats; D014978:Xenon / Q000494:pharmacology*
D018685:Anesthetics, Inhalation; D000697:Central Nervous System Stimulants; D018696:Neuroprotective Agents; D009498:Neurotoxins; D014978:Xenon; D008694:Methamphetamine; D009609:Nitrous Oxide